valsartan has been researched along with natriuretic peptide, brain in 119 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (8.40) | 29.6817 |
| 2010's | 56 (47.06) | 24.3611 |
| 2020's | 53 (44.54) | 2.80 |
| Authors | Studies |
|---|---|
| Anand, I; Bevilacqua, M; Cardano, P; Chiang, YT; Cohn, JN; Dunselman, PH; Holwerda, NJ; Judd, D; Latini, R; Maggioni, AP; Masson, S; Salio, M; Tognoni, G | 1 |
| Anand, IS; Chiang, YT; Cohn, JN; Fisher, LD; Glazer, RD; Latini, R; Maggioni, AP; Masson, S; Tognoni, G | 1 |
| Hukai, D; Ishii, C; Kanamori, T; Ohbayashi, Y; Ohnishi, M; Ohno, K; Okabayashi, T; Ozawa, T; Sakaguchi, T; Sichiri, G; Tanaka, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yokohama, H | 1 |
| Anzai, T; Hashimoto, K; Himeno, H; Imai, K; Kawana, M; Kitakaze, M; Koretsune, Y; Maruyama, S; Masaoka, Y; Matsubara, H; Matsuoka, T; Miyao, Y; Miyatake, K; Miyauchi, T; Nakamura, Y; Nomura, F; Okamoto, H; Ozono, K; Sekiya, M; Shinohara, H; Shintani, U; Shiraki, T; Takaoka, H; Tsutamoto, T; Yasumura, Y; Yokoya, K; Yokoyama, H | 1 |
| Anan, F; Hara, M; Nakagawa, M; Ooie, T; Saikawa, T; Takahashi, N; Yonemochi, H; Yoshimatsu, H; Yufu, K | 1 |
| Anand, IS; Cohn, JN; Florea, VG; Glazer, R; Hester, A; Kuskowski, MA; Latini, R; Masson, S; Mocarelli, P; Rector, T; Signorini, S | 1 |
| Hatori, T; Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Hino, M; Nakamae, H; Nakamae, M; Nakane, T; Ohta, K; Terada, Y; Tsumura, K; Yamane, T | 1 |
| Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tan, LB; Tognoni, G; Vago, T; Wong, M | 1 |
| Cohn, JN; Duprez, DA; Florea, ND; Jones, K | 1 |
| Bode, C; Braunwald, E; Cannon, CP; Lopez-Sendon, J; Lukashevich, V; Maboudian, M; McCabe, CH; Morrow, DA; Ogorek, M; Oude Ophuis, AJ; Rifai, N; Ruda, M; Ruzyllo, W; Scirica, BM; Swedberg, K | 1 |
| Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH | 1 |
| Baschiera, F; Botha, J; Brunel, P; Lacy, PS; Prescott, MF; Williams, B | 1 |
| Bransford, T; Gong, J; Kraigher-Krainer, E; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, B; Shah, A; Shi, V; Solomon, SD; Takeuchi, M; Voors, A; Zile, M | 1 |
| Desai, AS; Gong, J; Lefkowitz, MP; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, J; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Atar, D; Burnett, JC; Kompa, AR; Krum, H; Sangaralingham, SJ; von Lueder, TG; Wang, BH | 1 |
| Anand, IS; Cohn, JN; Kuskowski, M; Rector, TS; Snider, J | 1 |
| Bransford, T; Claggett, B; Jhund, PS; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, B; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Desai, AS; Gong, J; Lefkowitz, M; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Claggett, BL; Jhund, PS; Kraigher-Krainer, E; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, BM; Prescott, MF; Shah, AM; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Miller, R; Solomon, SD; Vardeny, O | 1 |
| Andersen, K; Arango, JL; Arnold, JM; Bělohlávek, J; Böhm, M; Boytsov, S; Burgess, LJ; Cabrera, W; Calvo, C; Chen, CH; Desai, AS; Duarte, YC; Dukat, A; Erglis, A; Fu, M; Gomez, E; Gong, J; Gonzàlez-Medina, A; Hagège, AA; Huang, J; Katova, T; Kiatchoosakun, S; Kim, KS; Kozan, Ö; Lefkowitz, MP; Llamas, EB; Martinez, F; McMurray, JJ; Mendoza, I; Merkely, B; Mosterd, A; Negrusz-Kawecka, M; Packer, M; Peuhkurinen, K; Ramires, FJ; Refsgaard, J; Rizkala, AR; Rosenthal, A; Rouleau, JL; Senni, M; Shi, VC; Sibulo, AS; Silva-Cardoso, J; Solomon, SD; Squire, IB; Starling, RC; Swedberg, K; Teerlink, JR; Vanhaecke, J; Vinereanu, D; Wong, RC; Zile, M | 1 |
| Chen, J; Hu, YJ; Peng, DF; Tang, SY | 1 |
| Białkowska, B; Birkner, E; Gabrysiak, A; Jacheć, W; Kalarus, Z; Kawecki, D; Nowalany-Kozielska, E; Romuk, E; Tomasik, A; Wojciechowska, C | 1 |
| Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY | 1 |
| Lang, CC; Singh, JS | 1 |
| Bělohlávek, J | 1 |
| Giannitsis, E; Huber, K; Jaffe, AS; Lindahl, B; Mair, J; Möckel, M; Müller, C; Plebani, M; Thygesen, K | 1 |
| Katrukha, AG; Semenov, AG | 1 |
| Albrecht, D; Averkov, O; Ayalasomayajula, S; Chandra, P; Jordaan, P; Kobalava, Z; Kotovskaya, Y; Langenickel, TH; Moiseev, V; Pal, P; Pavlikova, E; Prescott, MF; Rajman, I | 1 |
| Lippi, G; Sanchis-Gomar, F | 1 |
| Ahmed, A; Banach, M; Bielecka-Dabrowa, A; Misztal, M; Pietrucha, T; Rysz, J; Sakowicz, A; von Haehling, S | 1 |
| Blumenthal, RS; Gilotra, NA; Hsu, S; Lewsey, S; Mathews, L; Nwabueze, C; Okwuosa, IS; Princewill, O; Russell, SD | 1 |
| Díez, J | 1 |
| Hinder, M; Hirschhorn, E; Ihm, SH; Langenickel, TH; Lee, HY; Pal, P; Prescott, MF; Rhee, MY; Tan, RS; Tomlinson, B; Wang, TD; Yang, F | 1 |
| Claggett, BL; Desai, AS; Gong, J; McMurray, JJ; Packer, M; Prescott, MF; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Sabbah, HN | 1 |
| Guo, W; Ito, H; Momomura, S; Ohishi, T; Okino, N; Saito, Y; Tsutsui, H; Yamamoto, K | 1 |
| Clark, AL; Cleland, JGF; Dierckx, R; Kazmi, S; MacNamara, A; Pellicori, P; Shah, P; Urbinati, A; Zhang, J | 1 |
| Guo, J; Wong, PC; Zhang, A | 1 |
| Clerico, A; Di Tano, G | 1 |
| Chrysant, SG | 1 |
| Lindblad, AJ; McDonald, T; Sehn, E | 1 |
| Kałużna-Oleksy, M; Kolasa, J; Lelonek, M; Migaj, J; Nessler, J; Pawlak, A; Straburzyńska-Migaj, E | 1 |
| Cyrille, N; Elyahu, AY; Ramakrishna, H; Renew, JR | 1 |
| Balas, B; Bruce Wirta, S; Calado, F; Dworak, M; Engelhard, J; Grunow, SS; Klebs, S; Proenca, CC; Schindler, M; Schlienger, R; Viriato, D; Wachter, R | 1 |
| Anand, IS; Chow, SL; Daniels, LB; Maisel, AS; McCullough, PA | 1 |
| Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; Hernandez, AF; McCague, K; Morrow, DA; Rocha, RA; Velazquez, EJ | 1 |
| Butler, J; Fombu, E; Januzzi, JL; Maisel, A; McCague, K; Piña, IL; Prescott, MF; Riebman, JB; Solomon, S | 1 |
| Ayesta, A; Bover-Freire, R; De-Juan, J; Díez-Villanueva, P; Esteban-Fernández, A; García-Aguado, M; Gómez-Bueno, M; González-Saldívar, H; Iglesias, D; Iniesta, ÁM; Martínez-Sellés, M; Perea-Egido, JA; Rojas-González, A; Vicent, L | 2 |
| Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| Arrigo, M; Beauvais, F; Cohen-Solal, A; Launay, JM; Logeart, D; Nougué, H; Pezel, T; Picard, F; Sadoune, M; Vodovar, N | 1 |
| Fonarow, GC; Srivastava, PK | 1 |
| Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJV; Myhre, PL; Packer, M; Rouleau, JL; Shi, V; Solomon, SD; Swedberg, K; Vaduganathan, M; Zile, MR | 1 |
| D'Agostino, A; Dini, FL; Fabiani, I; Galeotti, GG; Mazzola, M; Pugliese, NR; Zywicki, V | 1 |
| Apple, FS; Burnett, JC; Gaggin, HK; Ibrahim, NE; Iyer, S; Januzzi, JL; McCarthy, CP; Mukai, R; Shrestha, S; Szymonifka, J | 1 |
| Anand, IS | 1 |
| Benson, L; Dahlström, U; Jhund, PS; Lund, LH; McMurray, JJV; Simpson, J | 1 |
| Ambrosy, AP; Braunwald, E; Desai, AS; DeVore, AD; Duffy, CI; Gurmu, Y; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| Ali, RH; Dizaye, K | 1 |
| Ewert, P; Hager, A; Maurer, SJ; Pujol Salvador, C; Schiele, S; Tutarel, O | 1 |
| Hryniewiecki, TT; Kodziszewska, K; Leszek, P; Sochanowicz, B; Witold, Ś | 1 |
| Anand, IS; Chandra, A; Claggett, BL; Ge, J; Lam, CSP; Lefkowitz, MP; Lewis, EF; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Vaduganathan, M; Van Veldhuisen, DJ; Wang, W; Zannad, F; Zile, MR | 1 |
| Artemieva, MM; Bloshchitsyna, MN; Feygina, EE; Katrukha, AG; Medvedeva, NA; Postnikov, AB; Semenov, AG; Tamm, NN | 1 |
| Apple, FS; Daniels, LB; Jaffe, A; Januzzi, J; Omland, T; Ordonez-Llanos, J | 1 |
| Abellas-Sequeiros, M; Alonso-Salinas, GL; Del Prado Díaz, S; Del Rey, JM; Zamorano, JL | 1 |
| Fernández-Ruiz, I | 1 |
| Ambrosy, AP; Braunwald, E; Chakraborty, H; DeVore, AD; Duffy, CI; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| Gao, Y; Hao, W; Hou, A; Luan, B; Wang, L; Xing, C; Zhao, H | 1 |
| Anand, IS; Anker, SD; Böhm, M; Claggett, BL; Lam, CSP; Lefkowitz, MP; McMurray, JJV; Pieske, B; Selvaraj, S; Shi, VC; Solomon, SD; Vaduganathan, M; Zannad, F | 1 |
| Januzzi, JL; Myhre, PL | 1 |
| Anand, IS; Chopra, VK; Claggett, BL; Cunningham, JW; Janssens, S; Jhund, PS; Kober, L; Lam, CSP; Lefkowitz, MP; McMurray, JJV; Packer, M; Pfeffer, MA; Prescott, MF; Rouleau, J; Shah, SJ; Shi, VC; Solomon, SD; Vaduganathan, M; Zannad, F; Zile, MR | 1 |
| DeVore, AD; Fonarow, GC; Fudim, M; Heidenreich, PA; Hernandez, AF; Matsouaka, RA; Sayeed, S; Velazquez, EJ; Xu, H; Yancy, CW | 1 |
| Arvanitakis, S; Elkouris, M; Katsianos, E; Pelonis, P; Siniorakis, E; Tertipi, A | 1 |
| Brito, D; Ferreira, J; Fonseca, C; Franco, F; Morais, J; Silva Cardoso, J | 1 |
| Node, K; Tanaka, A | 1 |
| Claggett, BL; Cunningham, JW; McMurray, JJV; Solomon, SD; Vaduganathan, M | 2 |
| Ambrosy, AP; Braunwald, E; Desvigne-Nickens, P; DeVore, AD; Gilotra, NA; Givertz, MM; Gorodeski, EZ; Greene, SJ; Gupta, D; Hernandez, AF; Lala, A; Lewis, GD; Mahr, C; Mann, DL; McNulty, SE; Mohammed, SF; Redfield, MM; Shah, P; Starling, RC; Vader, JM | 1 |
| Gronda, E; Iacoviello, M; Napoli, C | 1 |
| Fu, X; Wang, H | 1 |
| Chilbert, MR; Ciriello, DN; Rogers, KC; Rovelli, R; Woodruff, AE | 1 |
| Abdel-Latif, GA; ElMongy, NF; Elwahab, AHA; Hasan, RA; Louka, ML; Ramzy, MM; Schaalan, MF | 1 |
| Bao, W; Butylin, D; Noè, A; Pascual-Figal, D; Prescott, MF; Schwende, H; Senni, M; Wachter, R | 1 |
| Hu, P; Jin, D; Ke, Z; Wu, Y; Zhang, K; Zhang, Y | 1 |
| Danzi, GB; De Maria, R; Di Tano, G; Loffi, M; Verde, S | 1 |
| Abshire, M; Alexy, T; Barringhaus, KG; Blanco, R; Briasoulis, A; DeVore, AD; Dhingra, R; Duffy, CI; Dunlay, SM; Eckman, PM; Espinoza, J; Gupta, B; Hernandez, AF; Lala, A; Lowes, BD; Mentz, RJ; O'Brien, EC; Rodgers, JE; Shen, X; Simon, MA; Stehlik, J; Thomas, L; Vilaro, J; Wells, QS; Xu, H | 1 |
| Christophy, A; Heywood, JT; Jer, D; Kuo, RS; Mohan, RC; Pandey, AC; Srivastava, AV; Yoo, DH | 1 |
| Ferrara, F; La Porta, R; Vitiello, A | 1 |
| Casale, M; Correale, M; Crea, P; Dattilo, G; de Gregorio, C; Katsiki, N; Laterra, G; Luzza, F; Morabito, C; Signorelli, SS; Vaccaro, V | 1 |
| Al'Aref, SJ; Almarzooq, ZI; Butler, J; Devabhaktuni, SR; Fudim, M; Greene, SJ; Khan, MS; Mentz, RJ; Salah, HM | 1 |
| Imamura, T | 1 |
| Heywood, JT; Pandey, AC | 1 |
| Adams, V; Augstein, A; Barthel, P; Draskowski, R; Galli, R; Goto, K; Jannasch, A; Kirchhoff, V; Linke, A; Männel, A; Mittag, J; Schauer, A; Winzer, EB | 1 |
| Chen, Y; Cui, J; Liu, X; Pan, C; Pang, Z; Ren, Y; Tian, L; Yao, Z; Zhang, L | 1 |
| Ahn, KJ; Chung, WJ; Jang, AY; Kim, DH; Kwan, J; Yu, J | 1 |
| Alhan, A; Altay, H; Altın, C; Ataş, AE; Baş, MM; Çakmak, HA; Demirkan, B; Dereli, S; Durakoğlugil, ME; Ekici, B; Fahri Erkan, A; Karavelioğlu, Y; Kılıçaslan, B; Kılıçaslan, F; Kıvrak, T; Küçük, M; Olgun, FE; Özkan, H; Şabanoğlu, C; Tengiz, İ; Yaman, M; Yenerçağ, M; Yiğit, Z; Zoghi, M | 1 |
| Chun, KH; Ha, J; Kang, SM; Kim, H; Lee, CJ; Lee, S; Lee, SH; Oh, J; Park, S; Yoon, M | 1 |
| Goh, VJ; Hon, JS; Koh, N; Lim, CP; Sim, D; Teo, LLY; Teoh, CK | 1 |
| Bhatti, P; Bromage, DI; Cannata, A; DeCourcey, J; Holm, N; Huang, M; McDonagh, TA | 1 |
| Anstrom, KJ; Braunwald, E; Desvigne-Nickens, P; DeVore, AD; Givertz, MM; Gupta, D; Hernandez, AF; Kiernan, MS; Lala, A; Lewis, GD; Mahr, C; Mann, DL; Margulies, KB; McNulty, SE; Redfield, MM; Shah, P; Starling, RC; Vader, JM | 1 |
| Baldridge, A; Cowie, MR; Ibram, G; Pieske, B; Shah, SJ; Shi, V; Szeczoedy, P; Wachter, R; Zhao, Z | 1 |
| Claggett, B; Desai, AS; Fang, JC; Januzzi, JL; Mitchell, GF; Murphy, SP; Myhre, PL; Prescott, MF; Solomon, SD; Ward, JH | 1 |
| Andersen, UØ; Goetze, JP; Gustafsson, F; Hansen, LH; Mark, PD; Plomgaard, P; Prickett, TCR; Terzic, D; Thonsgaard, S; Wewer Albrechtsen, NJ | 1 |
| Du, H; Jiang, N; Li, X; Zhao, W | 1 |
| Claggett, BL; Desai, AS; Fang, JC; Mitchell, GF; Myhre, PL; Prescott, MF; Shah, AM; Solomon, SD; Ward, JH | 1 |
| Chen, C; Fan, L; Li, J; Li, X; Lv, Q; Tian, D; Zuo, C | 1 |
| Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE | 1 |
| Ageev, FT; Ovchinnikov, AG | 1 |
| Imamura, T; Kinugawa, K | 1 |
| Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH | 2 |
| Xu, Z; Yang, S; Zhang, X | 1 |
| Cohen-Solal, A; Laribi, S; Lassus, J; Launay, JM; Logeart, D; Michel, T; Nougué, H; Picard, F; Sadoune, M; Vodovar, N | 1 |
| Goetze, JP; Hansen, LH; Nersting, J; Terzic, D | 1 |
| Dodd, JD; Fox, R; Gallagher, J; Ledwidge, M; McDonald, K; McVeigh, N; Murphy, DJ; Ryan, F; Shorten, E; Sweeney, C; Watson, C; Zhou, S | 1 |
| Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Myhre, PL; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH | 1 |
| Agostoni, P; Banfi, C; Biondi, ML; Bonomi, A; Capra, N; Mapelli, M; Mattavelli, I; Palermo, P; Paolillo, S; Salvioni, E | 1 |
13 review(s) available for valsartan and natriuretic peptide, brain
| Article | Year |
|---|---|
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
Topics: Alternative Splicing; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Designer Drugs; Drug Combinations; Drug Therapy, Combination; Endothelin-1; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Natriuretic Peptides; Neprilysin; Peptidyl-Dipeptidase A; Protease Inhibitors; Receptors, Angiotensin; Renin-Angiotensin System; Snake Venoms; Tetrazoles; Valsartan | 2013 |
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Tetrazoles; Valsartan | 2014 |
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Hypertension; Indans; Natriuretic Peptide, Brain; Neprilysin; Propionates; Pyridines; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Stroke Volume; Tetrazoles; Thiazepines; Valsartan | 2015 |
Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Valsartan | 2016 |
The ABCs of managing systolic heart failure: Past, present, and future.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Resynchronization Therapy Devices; Defibrillators, Implantable; Digoxin; Diuretics; Drug Combinations; Evidence-Based Medicine; Exercise; Heart Failure; Heart-Assist Devices; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Practice Guidelines as Topic; Systole; Tetrazoles; Valsartan | 2016 |
Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Chronic Disease; Drug Combinations; Endothelin-1; Heart Failure; Humans; Natriuretic Agents; Natriuretic Peptide, Brain; Neprilysin; Receptors, Atrial Natriuretic Factor; Renin-Angiotensin System; Sympathetic Nervous System; Tetrazoles; Valsartan | 2017 |
Silent disease progression in clinically stable heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Apoptosis; Atrial Natriuretic Factor; Biphenyl Compounds; Calcium; Disease Progression; Diuretics; Drug Combinations; Fibrosis; Heart Failure; Humans; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Natriuretic Agents; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stress, Mechanical; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2017 |
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Clinical Trials as Topic; Cough; Cyclic GMP; Diuresis; Drug Combinations; Heart Failure; Heart Ventricles; Humans; Hypertension; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan; Vasodilation | 2017 |
B-Natriuretic Peptide Pathway Modulation for the Management of Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Disease Management; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Signal Transduction; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2018 |
Inpatient Initiation of Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Heart Failure; Hospitalization; Humans; Inpatients; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Valsartan | 2021 |
Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cause of Death; Drug Combinations; Heart Failure; Hospitalization; Humans; Mortality; Natriuretic Peptide, Brain; Peptide Fragments; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diuretics; Drug Combinations; Enalapril; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents | 2022 |
46 trial(s) available for valsartan and natriuretic peptide, brain
| Article | Year |
|---|---|
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Survival Rate; Tetrazoles; Time; Valine; Valsartan | 2002 |
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Biomarkers; Double-Blind Method; Follow-Up Studies; Heart Failure; Humans; Kinetics; Natriuretic Peptide, Brain; Norepinephrine; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan | 2003 |
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Coronary Disease; Delayed-Action Preparations; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Synergism; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Failure; Heart Function Tests; Humans; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Receptors, Angiotensin; Renin; Tetrazoles; Valine; Valsartan | 2004 |
Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Ankle; Aorta; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Perindopril; Prospective Studies; Pulse; Tetrazoles; Valine; Valsartan | 2005 |
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; C-Reactive Protein; Female; Heart Failure; Humans; Male; Middle Aged; Morbidity; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Tetrazoles; Valine; Valsartan | 2005 |
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Heart; Heart Failure; Humans; Male; Mediastinum; Middle Aged; Natriuretic Peptide, Brain; Observer Variation; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan | 2006 |
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Natriuretic Factor; Biomarkers; Cyclophosphamide; Doxorubicin; Female; Hemodynamics; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Prednisone; Tetrazoles; Valine; Valsartan; Vincristine | 2005 |
Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Comorbidity; Coronary Artery Disease; Disease Progression; Double-Blind Method; Exercise Test; Female; Fluorescein Angiography; Health Status Indicators; Heart Diseases; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; Predictive Value of Tests; Tetrazoles; Valine; Valsartan | 2007 |
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.
Topics: Acute Coronary Syndrome; Aged; Amides; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Female; Fumarates; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Cystatin C; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Potassium; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise.
Topics: Adult; Aged; Amides; Arginine; Blood Pressure; Demography; Endpoint Determination; Exercise; Female; Fumarates; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Renin; Renin-Angiotensin System; Systole; Tetrazoles; Valine; Valsartan | 2013 |
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valine; Valsartan | 2012 |
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure, Systolic; Hospitalization; Humans; Morbidity; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Single-Blind Method; Survival Rate; Tetrazoles; Valsartan | 2013 |
Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Female; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Receptors, Cell Surface; Regression Analysis; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Glomerular Filtration Rate; Heart Atria; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Troponin T; Valine; Valsartan | 2014 |
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Valsartan | 2015 |
Randomized placebo controlled blinded study to assess valsartan efficacy in preventing left ventricle remodeling in patients with dual chamber pacemaker--Rationale and design of the trial.
Topics: Atrioventricular Block; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Humans; Matrix Metalloproteinases; Natriuretic Peptide, Brain; Pacemaker, Artificial; Peptide Fragments; Research Design; Stroke Volume; Tumor Necrosis Factor-alpha; Valsartan; Ventricular Remodeling | 2015 |
[Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure].
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiotonic Agents; Chronic Disease; Czech Republic; Drug Combinations; Female; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Survival Rate; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2015 |
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biomarkers; Biphenyl Compounds; Chronic Disease; Drug Administration Schedule; Drug Combinations; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Russia; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Diuresis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Natriuresis; Natriuretic Peptide, Brain; Peptide Fragments; Sodium Chloride, Dietary; Tetrazoles; Time Factors; Valsartan | 2017 |
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Prospective Studies; Single-Blind Method; Stroke Volume; Treatment Outcome; Valsartan | 2016 |
Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Asian People; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Research Design; Single-Blind Method; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2017 |
What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Selection; Peptide Fragments; Retrospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2017 |
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
Topics: Administration, Oral; Aged; Aminobutyrates; Biphenyl Compounds; Cardiac Output, Low; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Safety; Peptide Fragments; Prognosis; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Follow-Up Studies; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Protein Precursors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2018 |
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Output, Low; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2019 |
In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Hospital Mortality; Hospitalization; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2019 |
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Tetrazoles; Valsartan | 2019 |
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.
Topics: Aminobutyrates; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Risk; Survival Analysis; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Discharge; Peptide Fragments; Tetrazoles; Valsartan | 2020 |
The Impact of Sacrubitril/Valsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Treatment Outcome; Troponin T; Valsartan; Ventricular Function, Left | 2020 |
Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Drug Monitoring; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Outcome Assessment, Health Care; Peptide Fragments; Sex Factors; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Protein Precursors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Betacoronavirus; Biphenyl Compounds; Cardiotonic Agents; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Early Termination of Clinical Trials; Glomerular Filtration Rate; Heart Failure; Heart Transplantation; Heart-Assist Devices; Hospitalization; Humans; Hypotension; Natriuretic Peptide, Brain; Pandemics; Peptide Fragments; Pneumonia, Viral; SARS-CoV-2; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Anterior Wall Myocardial Infarction; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Echocardiography; Enalapril; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2021 |
Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anterior Wall Myocardial Infarction; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Early Medical Intervention; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Postoperative Complications; Stroke Volume; Treatment Outcome; Valsartan | 2021 |
A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arterial Pressure; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Hormone Antagonists; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Oxidative Stress; Pulmonary Artery; Stroke Volume; Tetrazoles; Treatment Outcome; Troponin T; Valsartan | 2021 |
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Valsartan | 2022 |
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Stroke Volume; Valsartan; Walk Test | 2021 |
Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Neprilysin; Peptide Fragments; Sitagliptin Phosphate; Tetrazoles; Valsartan | 2022 |
The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
Topics: Adiponectin; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Carotid Intima-Media Thickness; Drug Combinations; Endothelium; Heart Failure; Humans; Hypertension; Matrix Metalloproteinase 9; Natriuretic Peptide, Brain; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial.
Topics: Aged; Aminobutyrates; Biomarkers; Biphenyl Compounds; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Troponin T; Valsartan | 2022 |
The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure.
Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Echocardiography; Enalapril; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Female; Heart Atria; Heart Failure; Humans; Hypertension; Male; Natriuretic Peptide, Brain; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2023 |
60 other study(ies) available for valsartan and natriuretic peptide, brain
| Article | Year |
|---|---|
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Disease Progression; Echocardiography; Heart Failure; Heart Ventricles; Humans; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stroke Volume; Survival Rate; Tetrazoles; Valine; Valsartan | 2006 |
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
Topics: Adrenergic beta-Antagonists; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diuretics; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Patient Selection; Platelet Aggregation Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2014 |
Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
Topics: Angiotensin II; Animals; Atorvastatin; Benzazepines; C-Reactive Protein; Cardio-Renal Syndrome; Case-Control Studies; Drug Synergism; Heptanoic Acids; Lipids; Male; Natriuretic Peptide, Brain; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2015 |
Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS).
Topics: Aged; Antihypertensive Agents; Atorvastatin; Benzazepines; C-Reactive Protein; Cardio-Renal Syndrome; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Protective Agents; Valsartan | 2015 |
Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Natriuretic Peptides; Neprilysin; Peptide Fragments; Predictive Value of Tests; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.
Topics: Aminobutyrates; Antibodies, Monoclonal; Biphenyl Compounds; Drug Combinations; Epitopes; Escherichia coli; Glycosylation; Heart Failure; Humans; Immunoassay; Limit of Detection; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Protein Precursors; Proteolysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tetrazoles; Valsartan | 2016 |
Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Dilated; Drug Combinations; Female; Genetic Markers; Genetic Predisposition to Disease; Heart Failure; Humans; Male; Middle Aged; Myocardial Ischemia; Natriuretic Peptide, Brain; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Stroke Volume; Syndecan-4; Tetrazoles; Transforming Growth Factor beta1; Valsartan | 2016 |
The renal and cardiovascular effects of natriuretic peptides.
Topics: Aminobutyrates; Atrial Natriuretic Factor; Biphenyl Compounds; Disease Progression; Drug Combinations; Enalapril; Heart Failure; Humans; Kidney; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Natriuretic Peptides; Tetrazoles; Valsartan | 2017 |
[The relationship between natriuretic peptides and neprilysin pathways: the clinical simplification against the complexity of biological systems].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biological Phenomena; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Valsartan | 2017 |
Sacubitril-valsartan: novel therapy for heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Tetrazoles; Valsartan | 2017 |
Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Outpatients; Patient Safety; Peptide Fragments; Poland; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2018 |
Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Body Mass Index; Comorbidity; Drug Combinations; Electronic Health Records; Female; Germany; Glycated Hemoglobin; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies; Sex Factors; Tetrazoles; Valsartan | 2018 |
Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Health Status; Heart Failure; Humans; Kidney; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Protease Inhibitors; Randomized Controlled Trials as Topic; Recovery of Function; Registries; Risk Factors; Spain; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2018 |
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; CD146 Antigen; Chronic Disease; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Fructosamine; Glucagon-Like Peptide 1; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Substance P; Tetrazoles; Treatment Outcome; Troponin I; Valsartan | 2019 |
Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Protease Inhibitors; Recovery of Function; Registries; Spain; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2019 |
Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Pharmacological Phenomena; Stroke Volume; Tetrazoles; Valsartan | 2019 |
What Explains the Benefits of ARNI Therapy in Heart Failure?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Tetrazoles; Valsartan | 2019 |
"Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Clinical Decision-Making; Drug Combinations; Eligibility Determination; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Selection; Peptide Fragments; Protease Inhibitors; Recovery of Function; Registries; Stroke Volume; Sweden; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2019 |
Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure.
Topics: Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Animals; Biomarkers; Biphenyl Compounds; Blood Pressure; Creatine Kinase, MB Form; Drug Combinations; Female; Fumarates; Heart Failure; Heart Rate; Kidney; Matrix Metalloproteinase 9; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Ramipril; Rats, Wistar; Renin; Tetrazoles; Troponin I; Valsartan | 2019 |
Sacubitril/valsartan for heart failure in adults with complex congenital heart disease.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Follow-Up Studies; Heart Defects, Congenital; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies; Tetrazoles; Valsartan | 2020 |
Searching for Optimal Prognostic Marker of Heart Failure Progression in the Era of ARNI.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Prognosis; Tetrazoles; Valsartan | 2019 |
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Topics: Age Factors; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Diuretics; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Randomized Controlled Trials as Topic; Self Efficacy; Severity of Illness Index; Sex Factors; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Animals; Biphenyl Compounds; Cross Reactions; Drug Combinations; Epitopes; Heart Failure; Humans; Immunoassay; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Rats, Wistar; Tetrazoles; Valsartan | 2019 |
Role of BNP vs NT-proBNP Testing in the Age of New Drug Therapies: Sacubitril-Valsartan.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan and B-type natriuretic peptide value: recalculating route.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Tetrazoles; Valsartan | 2020 |
Mechanisms of sacubitril-valsartan benefit in HFrEF.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan | 2019 |
The Challenges of NT-proBNP Testing in HFpEF: Shooting Arrows in the Wind.
Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Valsartan; Wind | 2020 |
Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Clinical Decision-Making; Drug Combinations; Eligibility Determination; Evidence-Based Medicine; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Admission; Patient Selection; Peptide Fragments; Protease Inhibitors; Randomized Controlled Trials as Topic; Recovery of Function; Registries; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Natriuretic Peptide, Brain; Neprilysin; Tetrazoles; Valsartan | 2020 |
Response to the Letter to the Editor "When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry".
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Natriuretic Peptide, Brain; Neprilysin; Tetrazoles; Valsartan | 2020 |
NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Reply: NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2020 |
The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan | 2020 |
A novel protective role of sacubitril/valsartan in cyclophosphamide induced lung injury in rats: impact of miRNA-150-3p on NF-κB/MAPK signaling trajectories.
Topics: Aminobutyrates; Animals; Antioxidants; Biphenyl Compounds; Bronchoalveolar Lavage Fluid; Cyclophosphamide; Cytokines; Drug Combinations; Gene Expression Regulation; Heme Oxygenase-1; Inflammation Mediators; L-Lactate Dehydrogenase; Leukocyte Count; Lung; Lung Injury; MAP Kinase Signaling System; MicroRNAs; NAD(P)H Dehydrogenase (Quinone); Natriuretic Peptide, Brain; NF-E2-Related Factor 2; NF-kappa B; Phosphorylation; Protective Agents; Rats; Tetrazoles; Valsartan | 2020 |
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Topics: Aftercare; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Patient Discharge; Peptide Fragments; Stroke Volume; Valsartan | 2020 |
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions].
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care Facilities; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Biphenyl Compounds; Chronic Disease; Continuity of Patient Care; Coronavirus Infections; COVID-19; Delivery of Health Care; Disease Progression; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Pandemics; Pneumonia, Viral; Quarantine; Recurrence; SARS-CoV-2; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Telephone; Tetrazoles; Valsartan; Withholding Treatment | 2020 |
PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Case-Control Studies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Reported Outcome Measures; Peptide Fragments; Preliminary Data; Propensity Score; Prospective Studies; Quality of Life; Tetrazoles; Valsartan | 2020 |
Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N-terminal pro B-type natriuretic peptide levels.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Tolerance; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Retrospective Studies; Valsartan | 2021 |
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Biphenyl Compounds; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Drug Combinations; Heart Failure; Homeostasis; Humans; Inflammation; Models, Theoretical; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Receptor, Angiotensin, Type 2; Tetrazoles; Valsartan; World Health Organization | 2021 |
Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study.
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Biphenyl Compounds; Defibrillators, Implantable; Drug Combinations; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Natriuretic Peptide, Brain; Outpatients; Peptide Fragments; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Implication of low dose sacubitril/valsartan.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Humans; Natriuretic Peptide, Brain; Tetrazoles; Valsartan | 2021 |
Re: Implication of low-dose sacubitril/valsartan.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Humans; Natriuretic Peptide, Brain; Tetrazoles; Valsartan | 2021 |
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Connectin; Cyclic GMP; Diastole; Disease Models, Animal; Drug Combinations; Electrocardiography; Female; Fibrosis; Glycated Hemoglobin; Heart Failure; Muscle, Skeletal; Muscular Atrophy; Natriuretic Peptide, Brain; Peptide Fragments; Phosphorylation; Rats, Mutant Strains; Valsartan; Ventricular Function, Left | 2021 |
Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients.
Topics: Aminobutyrates; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2021 |
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Female; Furosemide; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Retrospective Studies; Stroke Volume; Turkey; Valsartan; Ventricular Dysfunction, Left | 2021 |
Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2021 |
Angiotensin receptor-neprilysin inhibitor improves New York Heart Association class and N-terminal-pro B-type natriuretic peptide levels: initial experience in a Singapore single-centre cohort.
Topics: Angiotensin Receptor Antagonists; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; New York; Receptors, Angiotensin; Singapore; Stroke Volume; Valsartan | 2021 |
Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Black People; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Retrospective Studies; Stroke Volume; Valsartan; White People | 2022 |
Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Creatinine; Drug Combinations; Heart Failure; Humans; Hypertension; Natriuretic Peptide, Brain; Retrospective Studies; Tetrazoles; Uric Acid; Valsartan | 2022 |
Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A Single or Double-Edged Effect?
Topics: Aldosterone; Aminobutyrates; Anti-Inflammatory Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Cathepsin G; COVID-19 Drug Treatment; Cytokines; Gastrin-Releasing Peptide; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptides; Neprilysin; Renin; Respiratory Distress Syndrome; Tetrazoles; Valsartan | 2022 |
[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].
Topics: Aminobutyrates; Amyloidosis; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Hypertrophy, Left Ventricular; Natriuretic Peptide, Brain; Phenotype; Spironolactone; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Implication of sacubitril/valsartan on N-terminal pro B-type natriuretic peptide levels in hypertensive patients.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Hypertension; Natriuretic Peptide, Brain; Retrospective Studies; Tetrazoles; Valsartan | 2022 |
Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Troponin T; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
Topics: Aminobutyrates; Atrial Natriuretic Factor; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Guanosine Monophosphate; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Natriuretic Peptide, Brain; Stroke Volume; Troponin T; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2022 |
Deconvolution of BNP and NT-proBNP Immunoreactivities by Mass Spectrometry in Heart Failure and Sacubitril/Valsartan Treatment.
Topics: Aminobutyrates; Biomarkers; Dyspnea; Heart Failure; Humans; Mass Spectrometry; Natriuretic Peptide, Brain; Peptide Fragments; Serine; Valsartan | 2023 |
Next-Level Natriuretic Peptide Measurement.
Topics: Heart Failure; Humans; Mass Spectrometry; Natriuretic Peptide, Brain; Natriuretic Peptides; Peptide Fragments; Valsartan | 2023 |
Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptides; Phenotype; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways.
Topics: Aged; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2023 |